Daniel Long, DPhil, is the Senior Vice President, Drug Discovery, at Septerna. Dr. Long is a highly experienced drug hunter with a track record of leading high-performing teams that discover drug candidates and advance them through preclinical development and into clinical trials. His deep drug discovery expertise has resulted in several novel, innovative, and differentiated clinical compounds for a range of therapeutic indications.
Prior to joining Septerna, Dr. Long spent more 20 years at Theravance Biopharma, where he held numerous scientific leadership positions, including Vice President, Head of Medical Chemistry, Biology and Pharmacology. Dr. Long has been involved in the nomination of numerous development candidates, including nezulcitinib, an inhaled, lung-selective, pan-JAK inhibitor; axelopran, a peripherally-restricted opioid receptor antagonist; velusetrag, a 5-HT4 receptor agonist; and cefilavancin, a glycopeptide-cephalosporin heterodimer antibiotic.
Dr. Long received his BA, MA and DPhil degrees in Chemistry from the University of Oxford and completed an industrial post-doctoral fellowship at DuPont Pharmaceuticals.